Skip to main content

Dutch regulator clears 350 hectares of EVOCA NG trials for Biotalys, and the harvest may be sold

The Dutch Ctgb has approved large-scale EVOCA NG trials on up to 150 hectares of tomatoes, 150 of cucumbers and 50 of strawberries.

Dutch regulator clears 350 hectares of EVOCA NG trials for Biotalys, and the harvest may be sold

Biotalys, the Ghent-based crop protection company listed on Euronext Brussels as BTLS, said on 3 November 2026 that the Dutch Board for the Authorisation of Plant Protection Products and Biocides, the Ctgb, has approved large-scale commercial field trials of EVOCA NG. The approval covers up to 150 hectares of tomatoes, 150 hectares of cucumbers and 50 hectares of strawberries, and produce harvested from the trial crops may enter the food chain.

EVOCA NG is a next generation protein-based biofungicide candidate built on the company's AGROBODY technology, which Biotalys expects to be its first commercial biofungicide. It carries the same bioactive ingredient as the first generation EVOCA and targets Botrytis, or grey mould, and powdery mildew in fruit and vegetable crops. Biotalys puts the combined market for those two diseases at around 1.1 billion dollars, citing Kynetec 2020 and its own analysis, and plans a launch in the United States and the European Union in 2029.

The regulatory position differs on either side of the Atlantic. EVOCA received approval from the United States Environmental Protection Agency in December 2025 and state approvals in Florida and California during 2026, while the European review is still running. An EVOCA approval in Europe would open the way for EVOCA NG to be submitted, which is why the Dutch trials matter beyond their agronomy: they build a commercial record under a regulator that has already granted the unusual exemption of letting unregistered-product crops be sold.

The step up in scale is the part worth reading twice. When the Ctgb cleared the first large-scale demonstration programme for EVOCA in September 2024, it covered 40 hectares of tomatoes, 20 hectares of cucumbers and 10 hectares of strawberries. The new clearance is five times that area. Growers who ran the earlier programme are on the record in the company's announcement. Noud Dings of Brookberries said, “We applied EVOCA on 3.7 hectares of strawberries with great results,” and Rob van Enckevort of De Peelkroon said, “For a second year in a row, we successfully used EVOCA against powdery mildew in strawberries.” Chief executive Carlo Boutton said the approval of the demonstration programme “marks an important milestone for our company.”

Why it matters for AgTech founders: in biologicals the regulatory pathway is the product roadmap, and this is a worked example of how to monetise the waiting years. A pre-registration demonstration programme in which the harvest can legally be sold is worth far more than a trial plot, because it generates grower references, real application data and commercial habit four years ahead of launch, in the member state that acts as rapporteur for the European dossier. The flip side is the capital arithmetic. A company that has been public since 2021 is still pointing at 2029 for first revenue, and every founder building a protein or microbial active should price that gap into the raise rather than the pitch. Two practical questions follow. Does your jurisdiction offer a trial exemption that permits sale of the treated crop, and have you chosen the rapporteur state on regulatory speed rather than market size?

Source: GlobeNewswire

Dutch regulator clears 350 hectares of EVOCA NG trials for Biotalys, and the harvest may be sold

Ctgb has cleared Biotalys to run commercial-scale demonstration trials of its protein-based biofungicide on Dutch greenhouse crops, and growers may put the produce into the food chain.

By Dirk Vandenhirtz

· Biologicals · Europe · 3 min

Biotalys, the Ghent-based crop protection company listed on Euronext Brussels as BTLS, said on 3 November 2026 that the Dutch Board for the Authorisation of Plant Protection Products and Biocides, the Ctgb, has approved large-scale commercial field trials of EVOCA NG. The approval covers up to 150 hectares of tomatoes, 150 hectares of cucumbers and 50 hectares of strawberries, and produce harvested from the trial crops may enter the food chain.

EVOCA NG is a next generation protein-based biofungicide candidate built on the company's AGROBODY technology, which Biotalys expects to be its first commercial biofungicide. It carries the same bioactive ingredient as the first generation EVOCA and targets Botrytis, or grey mould, and powdery mildew in fruit and vegetable crops. Biotalys puts the combined market for those two diseases at around 1.1 billion dollars, citing Kynetec 2020 and its own analysis, and plans a launch in the United States and the European Union in 2029.

The regulatory position differs on either side of the Atlantic. EVOCA received approval from the United States Environmental Protection Agency in December 2025 and state approvals in Florida and California during 2026, while the European review is still running. An EVOCA approval in Europe would open the way for EVOCA NG to be submitted, which is why the Dutch trials matter beyond their agronomy: they build a commercial record under a regulator that has already granted the unusual exemption of letting unregistered-product crops be sold.

The step up in scale is the part worth reading twice. When the Ctgb cleared the first large-scale demonstration programme for EVOCA in September 2024, it covered 40 hectares of tomatoes, 20 hectares of cucumbers and 10 hectares of strawberries. The new clearance is five times that area. Growers who ran the earlier programme are on the record in the company's announcement. Noud Dings of Brookberries said, “We applied EVOCA on 3.7 hectares of strawberries with great results,” and Rob van Enckevort of De Peelkroon said, “For a second year in a row, we successfully used EVOCA against powdery mildew in strawberries.” Chief executive Carlo Boutton said the approval of the demonstration programme “marks an important milestone for our company.”

Why it matters for AgTech founders: in biologicals the regulatory pathway is the product roadmap, and this is a worked example of how to monetise the waiting years. A pre-registration demonstration programme in which the harvest can legally be sold is worth far more than a trial plot, because it generates grower references, real application data and commercial habit four years ahead of launch, in the member state that acts as rapporteur for the European dossier. The flip side is the capital arithmetic. A company that has been public since 2021 is still pointing at 2029 for first revenue, and every founder building a protein or microbial active should price that gap into the raise rather than the pitch. Two practical questions follow. Does your jurisdiction offer a trial exemption that permits sale of the treated crop, and have you chosen the rapporteur state on regulatory speed rather than market size?

Source: GlobeNewswire

Back to AgTech News